Use of combined hormonal contraception and stroke: A case‐control study of the impact of migraine type and estrogen dose on ischemic stroke risk

Abstract

Overall stroke risk in our cohort of CHC users was low. When CHCs are used in those with migraine, formulations containing ≤30 μg EE are preferred. Shared decision-making should include discussions about ischemic stroke risks in patients with migraine, even those without aura.